ストックスクリーナーアプリを入手
1.18
0.84%
-0.01
プレマーケット:
1.20
0.02
+1.69%
Spero Therapeutics Inc (SPRO) 最新ニュース
SPRO|Spero Therapeutics Inc|Price:1.170|Chg%:-0.020 - TradingKey
Spero Therapeutics Appoints Dr. Debra Jeske Zack Chief Medical Officer to Lead SP001 Development - citybiz
Spero Therapeutics names Debra Zack as chief medical officer - Investing.com
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer - The Manila Times
Spero Therapeutics names Debra Zack as chief medical officer By Investing.com - Investing.com Canada
Spero's Phase 2-Ready Antibody Has a New Clinical Lead - Stock Titan
Spero Therapeutics Inc (SPRO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Spero Therapeutics Inc (SPRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Spero Therapeutics Inc (SPRO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
SPRO|Spero Therapeutics Inc|Price:1.195|Chg%:+0.005 - TradingKey
Spero Therapeutics Inc (SPRO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Spero Therapeutics Secures $105 Million Royalty Financing and Exclusive License for SP001 - Global Legal Chronicle
SPRO stock holds its ground on Spero Therapeutics financing and pipeline - Ad-hoc-news.de
Enterprise value to EBITDA forward of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView
Enterprise value to revenue forward of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView
Price to earnings forward of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView
Price to book forward of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView
Price to sales forward of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView
Innovent licenses IBI355 rights to Spero for up to $1.1bn - Yahoo Finance
Spero Therapeutics (SPRO) Secures $105M Financing and $1.1B Lice - GuruFocus
Spero Therapeutics secures $105 million royalty financing - The Pharma Letter
Spero licenses anti-CD40L antibody from Innovent for $1.1bn By Investing.com - Investing.com South Africa
Spero Therapeutics (SPRO) Secures Exclusive License for IBI355 - GuruFocus
Spero Therapeutics: 'Buy' Utebzi Royalty Deal For Funding And SP001 In-Licensing (SPRO) - Seeking Alpha
Spero licenses anti-CD40L antibody from Innovent for $1.1bn - Investing.com UK
Spero signs $1.1 billion SP001 licensing deal - grafa.com
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion - Reuters
Spero Therapeutics secures $105m financing for drug development By Investing.com - Investing.com India
Spero Therapeutics (SPRO) Secures $105M Financing and $1.1B Licensing Agreement - GuruFocus
Spero Therapeutics Secures $105 Million Royalty Financing to Advance Immunology Pipeline - citybiz
Spero in-licenses Innovent’s antibody therapy (SPRO:NASDAQ) - Seeking Alpha
Spero Therapeutics Licenses Immunology Drug Candidate From Innovent, Recieves $105 Million Financing - Moomoo
Spero Therapeutics (SPRO) Secures $105M Financing to Advance Imm - GuruFocus
Spero Therapeutics secures $105m financing for drug development - Investing.com
Spero Therapeutics Lands $105 Million Royalty Financing to Advance SP001 Development (SPRO) - Yahoo Finance
Spero Therapeutics Licenses CD40L Antibody With Up to $1.05B Milestones, Secures $105M Royalty Financing - TradingView
Spero Therapeutics (Nasdaq: SPRO) inks SP001 deal and $105M royalty financing - Stock Titan
Spero Therapeutics shares fall after $105M KKR deal By Investing.com - Investing.com South Africa
Spero Therapeutics shares fall after $105M KKR deal - Investing.com UK
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties - The Manila Times
Spero Therapeutics Secures $105 Million Royalty Financing to Advance SP001 and Extend Cash Runway Through Second Half of 2029 - Quiver Quantitative
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody - The Manila Times
Spero's $105M deal will support Phase 2 immunology drug SP001 - Stock Titan
Cambridge biotech strikes $1.1B deal with Chinese partner, shifts to immunology - The Business Journals
Enterprise value to EBIT forward of Spero Therapeutics, Inc. – MUN:2HA - TradingView
MSN Money - MSN
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors - Yahoo! Finance Canada
Spero Therapeutics outlines its antibiotic pipeline as investors track regulatory progress - ad-hoc-news.de
Kailera Appoints New Chief Corporate Affairs Officer - Intellectia AI
Spero Therapeutics, Inc.(NasdaqGS: SPRO) added to Russell 3000E Growth Benchmark - marketscreener.com
Spero Therapeutics, Inc.(NasdaqGS: SPRO) added to Russell 3000E Index - marketscreener.com
Spero Therapeutics, Inc.(NasdaqGS: SPRO) added to Russell Microcap Index - marketscreener.com
Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Form 4 Spero Therapeutics Inc For: 25 June By Investing.com - Investing.com South Africa
Spero Therapeutics, Inc. Actuals & Estimates (NASDAQ:SPRO) - TradingView
Spero Therapeutics, Inc. Actuals & Estimates (BOATS:SPRO) - TradingView
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):